Rat TNF-Related Apoptosis-Inducing Ligand (rTRAIL)-Expressing Rat-Adipose-Derived Stem Cells (rADSC) Moderately Limit Growth of Rat Mammary Cancer Cells—A Pilot Study

Background: Adipose-derived stem cells (ADSCs) are readily harvestable, tumour-homing cells that have been engineered as vehicles for antitumour agents. TNF-related apoptosis-inducing ligand (TRAIL) selectively triggers apoptosis in many cancer cells through death receptors DR4/DR5, while sparing most healthy cells. To date, only human TRAIL has been studied in such delivery systems; a fully homologous rat model (rat TRAIL delivered by rat ADSC) has not been tested, despite being essential for future syngeneic in vivo studies. Methods: In this pilot, exploratory study, we lentivirally transduced rat ADSC (rADSC) to express myc-tagged rat TRAIL, characterized the expression of TRAIL-pathway components in rADSC and three rat mammary carcinoma cell lines (RBA, HH-16.cl.4, SHZ-88) at the mRNA and protein levels, and assessed the antitumour effect of rTRAIL-rADSC using recombinant TRAIL dose–response, supernatant transfer, direct co-culture, and nine-day insert co-culture assays. Results: rADSCs were successfully transduced and produced cell-associated rat TRAIL (66.2 pg per 50,000 cells versus 4.4–5.7 pg in controls; p < 0.05); this ELISA measures total cell-associated (intracellular plus membrane-anchored) TRAIL rather than soluble TRAIL. rADSC expressed markedly higher levels of the decoy molecule osteoprotegerin and of DR4/DR5 than the cancer cells. Two of three cancer lines (RBA, HH-16.cl.4) were susceptible to rat TRAIL, and rTRAIL-rADSC reduced their growth and increased the proportion of dead cells, with morphological features compatible with both apoptosis and necrosis, most markedly in HH-16.cl.4; the effect was separable from the empty-vector control in HH-16.cl.4 but not in RBA. Conclusions: In this pilot study, homologous rat TRAIL delivered by rADSC is feasible and increases cell death in TRAIL-susceptible rat mammary cancer cells, but the effect is moderate at most, contact-dependent, and in one of two susceptible lines not attributable to TRAIL itself. These findings define both the potential and the limitations of a fully translational rat model of TRAIL-based biologic brachytherapy and provide a foundation for future in vivo studies.

Authors

Institutions

Publication Details

Journal
Current Issues in Molecular Biology
Published
2026-09-15
DOI
https://doi.org/10.3390/cimb48090941
Primary Topic
Cell death mechanisms and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Rat TNF-Related Apoptosis-Inducing Ligand (rTRAIL)-Expressing Rat-Adipose-Derived Stem Cells (rADSC) Moderately Limit Growth of Rat Mammary Cancer Cells—A Pilot Study

Mateusz Gotowiec, Paweł Włodarski, Wiktor Pascal, Antoni Smoliński
Current Issues in Molecular Biology
Cell death mechanisms and regulation
article

Rat TNF-Related Apoptosis-Inducing Ligand (rTRAIL)-Expressing Rat-Adipose-Derived Stem Cells (rADSC) Moderately Limit Growth of Rat Mammary Cancer Cells—A Pilot Study

Mateusz Gotowiec, Paweł Włodarski, Wiktor Pascal, Antoni Smoliński
article en

Abstract

Background: Adipose-derived stem cells (ADSCs) are readily harvestable, tumour-homing cells that have been engineered as vehicles for antitumour agents. TNF-related apoptosis-inducing ligand (TRAIL) selectively triggers apoptosis in many cancer cells through death receptors DR4/DR5, while sparing most healthy cells. To date, only human TRAIL has been studied in such delivery systems; a fully homologous rat model (rat TRAIL delivered by rat ADSC) has not been tested, despite being essential for future syngeneic in vivo studies. Methods: In this pilot, exploratory study, we lentivirally transduced rat ADSC (rADSC) to express myc-tagged rat TRAIL, characterized the expression of TRAIL-pathway components in rADSC and three rat mammary carcinoma cell lines (RBA, HH-16.cl.4, SHZ-88) at the mRNA and protein levels, and assessed the antitumour effect of rTRAIL-rADSC using recombinant TRAIL dose–response, supernatant transfer, direct co-culture, and nine-day insert co-culture assays. Results: rADSCs were successfully transduced and produced cell-associated rat TRAIL (66.2 pg per 50,000 cells versus 4.4–5.7 pg in controls; p < 0.05); this ELISA measures total cell-associated (intracellular plus membrane-anchored) TRAIL rather than soluble TRAIL. rADSC expressed markedly higher levels of the decoy molecule osteoprotegerin and of DR4/DR5 than the cancer cells. Two of three cancer lines (RBA, HH-16.cl.4) were susceptible to rat TRAIL, and rTRAIL-rADSC reduced their growth and increased the proportion of dead cells, with morphological features compatible with both apoptosis and necrosis, most markedly in HH-16.cl.4; the effect was separable from the empty-vector control in HH-16.cl.4 but not in RBA. Conclusions: In this pilot study, homologous rat TRAIL delivered by rADSC is feasible and increases cell death in TRAIL-susceptible rat mammary cancer cells, but the effect is moderate at most, contact-dependent, and in one of two susceptible lines not attributable to TRAIL itself. These findings define both the potential and the limitations of a fully translational rat model of TRAIL-based biologic brachytherapy and provide a foundation for future in vivo studies.

Current Issues in Molecular BiologyVol. 48(9)
Medical University of Warsaw (PL)
Good health and well-being
Openalex Percentile: Top 18%
Cell death mechanisms and regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.